COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
Just Released: Military Training Technology Report October 2024 now available to read
How the latest portable simulation solutions can deliver JTAC training wherever it is needed
-
Irish defence budget increased by just €100 million despite €25 billion surplus
The budget of more than €1.3 billion is a record figure for the Irish Defence Forces but almost a quarter is to meet to meet the pensions costs of Defence Forces Veterans and their dependents.
-
Just released: Night Vision & Situational Awareness Technology Report 2024 now available to read
How night vision devices and soldier-worn sensors are underpinning advanced tactical C4ISR capabilities
-
How temporary funding could affect the US military’s critical acquisition programmes
Operating under continuing resolutions would affect Patriot, Virginia-class, Columbia-class and B-21 programmes.
-
Brazil’s proposed $23.7 billion defence budget targets GDP-linked military funding
Brazil’s 2025 budget proposals will see a 5.9% increase in defence spending, with funds allocated for key programmes including the procurement of helicopters, armoured vehicles and nuclear-powered submarines, despite looming fiscal challenges.